An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
|23||Not yet recruiting||
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
† Indicates status has not been verified in more than two years